Summary: The Drugs, Honestly

Thomas Brennan is 74, and he has a yellow legal pad with eleven questions on it. His wife Alice, 71, has added three more in the margins. Thomas was diagnosed with early-stage Alzheimer’s eight months ago, amyloid-positive by PET scan. His neurologist has presented lecanemab as a treatment option. Thomas and Alice have spent two months reading about it: articles describing it as a breakthrough, articles describing it as a dangerous overpromise, and nothing in between that explains what 27% slowing of decline means in the life of a man who still does his own taxes and walks two miles every morning.

Lecanemab and donanemab are monoclonal antibodies that clear amyloid-beta plaques from the brain. Lecanemab received full FDA approval in July 2023, donanemab in July 2024. Clinical trials showed both drugs slow cognitive decline by approximately 27% to 35% over eighteen months in early-stage, amyloid-positive patients. What the drugs do not do: repair dead neurons, prevent tau protein accumulation, restore lost function, reverse the disease, or cure it.

The translation of 27% into daily life is the section that matters most, because it is the section almost nobody writes. The placebo group progressed by approximately 1.66 points on the CDR-SB scale over eighteen months. The treatment group progressed by approximately 1.21 points. The difference is 0.45 points on an eighteen-point scale. Statistically significant. A real effect. On a day-to-day basis, not something most families would notice. Translation: a few more months of preserved function before the next measurable decline, spread over a year and a half.

Both drugs are approved for early-stage patients only, require confirmed amyloid-positive status, and carry ARIA risk, a safety concern involving brain swelling and microhemorrhages that occurs in approximately 21% of lecanemab-treated patients. APOE4 gene carriers face higher risk. Three deaths were reported in the lecanemab trial with contested causality. Monitoring requires regular MRIs during treatment.

The cost is approximately $26,500 to $32,000 per year. Medicare covers both drugs with prior authorization. The cost extends beyond the drug itself: PET scans, biweekly infusion visits, monitoring MRIs. The geographic barrier is real. A patient twelve miles from an infusion center can manage the schedule. A patient two hundred miles away may not. The patients most likely to benefit from early treatment are the patients most likely to be diagnosed early, and patients diagnosed early are disproportionately white, insured, and urban.

The pipeline beyond current drugs is active. Anti-tau therapies are in development. GLP-1 receptor agonists are in Alzheimer’s trials. Subcutaneous lecanemab formulations could replace biweekly infusions. The honest timeline for meaningful new options: three to five years.

Thomas proceeds with lecanemab. He is amyloid-positive, early stage, with moderate ARIA risk, and lives near an infusion center. Alice understands what 27% means now, precisely, because their neurologist spent twenty minutes on that question alone. The treatment buys time. Thomas intends to spend the time well. The drugs, honestly, are modest and real. The clarity to make the decision well was the thing that was missing, and it was never a pharmacological problem.

Read the full article on BlueMirror.life.